DashboardAll companies
Run this on your own research
Healthcare · Medical Instruments & Supplies

Terumo Corporation

4543JPX¥2,399−¥31 (−1.26%)Market closed

Price Chart

Daily

Key facts

Market Cap
¥3.54T
P/E
26.0x
P/B
2.23x
ROE
9.2%

Terumo Corporation

Healthcare · Medical Instruments & Supplies · FY 2026

Terumo Corporation is a leading medical device and healthcare company that plays a significant role in the global health sector. Founded in 1921 and headquartered in Tokyo, Japan, Terumo specializes in the development, production, and distribution of a wide range of medical technologies and equipment. Its primary offerings include cardiovascular systems, blood management products, neuro-intervention devices, and general hospital equipment, highlighting its contribution to critical sectors such as cardiology, radiology, and blood transfusion services. Terumo’s cardiovascular products, including stents and catheters, are used extensively in minimally invasive procedures, which are crucial for patient recovery and healthcare efficiency. With a prominent presence in over 160 countries, Terumo Corporation is recognized for its commitment to medical innovation and healthcare improvements, showing a substantial impact on patient care and hospital management. The company continuously invests in research and development to expand its portfolio, ensuring state-of-the-art solutions that meet evolving medical needs worldwide.

CEO
Mr. Hikaru Samejima
Employees
30,207
Website
terumo.com

Company Statistics

Valuation

P/E
26.0x
P/B
2.23x
P/S
3.13x
EV/EBITDA
13.1x
P/FCF
27.5x

Margins

Gross
52.5%
EBITDA
24.5%
Operating
15.6%
Pre-Tax
15.7%
Net
12.0%

Returns

ROA
6.6%
ROE
9.2%
ROIC
8.8%

Growth (CAGR)

Rev 3Yr
11.3%
Rev 5Yr
13.0%
Op Inc 3Yr
14.5%
Net Inc 3Yr
15.0%

Financial Health

Cash & Cash Equivalents
¥280.49B
Net Debt
¥447.23B
Debt/Equity
45.9%
Interest Cov
—

Profile

Revenue
¥1.13T
Shares Out
—
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Terumo Corporation (4543) Stock Forecast 2026 ¥2,399 — Price, Financials & Analyst Targets | AlphaLenz